LQDA Stock Catalyst: Liquidia Corp Announces Global Settlement with United Therapeutics

Oct 13, 2026 · 5:45pm ET

Ensures continued commercialization of YUTREPIA in PAH

Max move

+62.4%

High of day $43.54

Sparker timei

5:45pm ET

LQDA · Oct 13, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Liquidia Corp and United Therapeutics have announced a global settlement that resolves all pending litigation between the two companies. This agreement ensures the continued commercialization of Liquidia's YUTREPIA for the treatment of pulmonary arterial hypertension (PAH).

The settlement terms have been finalized, marking the end of legal disputes that could have impacted the availability of YUTREPIA. The agreement allows Liquidia to proceed with its commercial plans without further legal hindrance.

Liquidia Corp has a free float of 66,084,413 shares and 89,508,891 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time LQDA sparks.

Download Sniper App →

Catch the next LQDA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

LQDA Stock Catalyst: Liquidia Corp Announces Global Settlement with United Therapeutics

LQDA · Oct 13, 2026

LQDA · Oct 13, 2026

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.